文献速递神经MR

临床常规中未经MRI协议标准化即可测量脑萎缩的可行性:MS-MRIUS纵向观察性多中心真实世界复发缓解型MS患者研究结果

Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS.
PubMed 文献 · AJNR Am J Neuroradiol · 2017-11-23

MS-MRIUS是一项33中心回顾性研究,纳入590例开始芬戈莫德治疗的复发缓解型MS患者,随访16个月,使用未标准化1.5T或3T脑MRI评估脑萎缩。T2-FLAIR上侧脑室体积百分比变化在585例(99.2%)患者中可评估,而2D-T1WI和3D-T1WI的纵向配对分别仅425例(72%)和166例(28.2%);排除更换扫描仪后,T2-FLAIR侧脑室体积百分比变化可分析388例(65.8%),2D-T1WI脑体积百分比变化和侧脑室体积百分比变化分别可分析259例(43.9%)和257例(43.6%),3D-T1WI两者均可分析110例(18.6%)。中位年化脑体积百分比变化2D-T1WI为-0.31%、3D-T1WI为-0.38%;中位年化侧脑室体积百分比变化2D-T1WI为0.95%、3D-T1WI为1.47%、T2-FLAIR为0.90%。结论认为T2-FLAIR估算侧脑室体积百分比变化比2D/3D-T1WI的脑体积百分比变化或侧脑室体积百分比变化更易评估;3D-T1WI脑体积百分比变化仍是金标准并应鼓励用于未来前瞻性研究,但当历史或其他实际限制影响3D-T1WI脑体积百分比变化可用性时,T2-FLAIR衍生的侧脑室体积百分比变化可能是更可行的替代指标。

要点

  • 临床常规未标准化MRI协议下,T2-FLAIR侧脑室体积百分比变化可分析率(65.8%)高于2D-T1WI脑体积百分比变化(43.9%)和3D-T1WI脑体积百分比变化(18.6%)。
  • 中位年化侧脑室体积百分比变化T2-FLAIR为0.90%,低于2D-T1WI的0.95%和3D-T1WI的1.47%。
  • 3D-T1WI脑体积百分比变化仍是金标准,但T2-FLAIR侧脑室体积百分比变化在3D-T1WI不可用时可能是更可行的替代指标。

核心结论

  • 在这项观察性回顾性研究中,T2-FLAIR估算侧脑室体积百分比变化比2D或3D-T1WI的脑体积百分比变化或侧脑室体积百分比变化更易评估;3D-T1WI脑体积百分比变化仍是金标准并应鼓励用于未来前瞻性研究,但当历史或其他实际限制影响3D-T1WI脑体积百分比变化可用性时,T2-FLAIR衍生的侧脑室体积百分比变化可能是更可行的替代指标。

研究设计与样本

  • 多中心(33个中心)回顾性研究,纳入590例开始芬戈莫德治疗的复发缓解型MS患者,随访16个月;使用基线期和随访期在1.5T或3T扫描仪上预先采集、未标准化协议的脑MRI检查,以模拟真实世界情况。

关键影像表现/征象

  • T2-FLAIR纵向配对检查585例(99.2%),2D-T1WI纵向配对425例(72%),3D-T1WI纵向配对166例(28.2%)。
  • 排除更换扫描仪的MRI检查后,T2-FLAIR侧脑室体积百分比变化可分析388例(65.8%),2D-T1WI脑体积百分比变化和侧脑室体积百分比变化分别可分析259例(43.9%)和257例(43.6%),3D-T1WI两者均可分析110例(18.6%)。
  • 中位年化脑体积百分比变化2D-T1WI为-0.31%,3D-T1WI为-0.38%。
  • 中位年化侧脑室体积百分比变化2D-T1WI为0.95%,3D-T1WI为1.47%,T2-FLAIR为0.90%。

诊断标准与关键数值

  • 脑体积百分比变化由结构图像评估联合萎缩归一化(SIENA)在2D-T1加权成像和3D-T1WI上测量。
  • 侧脑室体积百分比变化由VIENA在2D-T1WI和3D-T1WI上测量,以及由NeuroSTREAM在T2-FLAIR检查上测量。

临床应用与阅片要点

  • 在临床常规未标准化MRI协议下,可优先尝试用T2-FLAIR估算侧脑室体积百分比变化以评估脑萎缩。
  • 3D-T1WI脑体积百分比变化仍是金标准,未来前瞻性研究应鼓励采用。
  • 当历史或其他实际限制影响3D-T1WI脑体积百分比变化可用性时,T2-FLAIR衍生的侧脑室体积百分比变化可能是更可行的替代指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Feasibility of brain atrophy measurement in patients with MS in clinical routine, without prior standardization of the MRI protocol, is unknown. Our aim was to investigate the feasibility of brain atrophy measurement in patients with MS in clinical routine.

MATERIALS AND METHODS: Multiple Sclerosis and Clinical Outcome and MR Imaging in the United States (MS-MRIUS) is a multicenter (33 sites), retrospective study that included patients with relapsing-remitting MS who began treatment with fingolimod. Brain MR imaging examinations previously acquired at the baseline and follow-up periods on 1.5T or 3T scanners with no prior standardization were used, to resemble a real-world situation. Brain atrophy outcomes included the percentage brain volume change measured by structural image evaluation with normalization of atrophy on 2D-T1-weighted imaging and 3D-T1WI and the percentage lateral ventricle volume change, measured by VIENA on 2D-T1WI and 3D-T1WI and NeuroSTREAM on T2-fluid-attenuated inversion recovery examinations.

RESULTS: A total of 590 patients, followed for 16 months, were included. There were 585 (99.2%) T2-FLAIR, 425 (72%) 2D-T1WI, and 166 (28.2%) 3D-T1WI longitudinal pairs of examinations available. Excluding MR imaging examinations with scanner changes, the analyses were available on 388 (65.8%) patients on T2-FLAIR for the percentage lateral ventricle volume change, 259 and 257 (43.9% and 43.6%, respectively) on 2D-T1WI for the percentage brain volume change and the percentage lateral ventricle volume change, and 110 (18.6%) on 3D-T1WI for the percentage brain volume change and percentage lateral ventricle volume change. The median annualized percentage brain volume change was -0.31% on 2D-T1WI and -0.38% on 3D-T1WI. The median annualized percentage lateral ventricle volume change was 0.95% on 2D-T1WI, 1.47% on 3D-T1WI, and 0.90% on T2-FLAIR.

CONCLUSIONS: Brain atrophy was more readily assessed by estimating the percentage lateral ventricle volume change on T2-FLAIR compared with the percentage brain volume change or percentage lateral ventricle volume change using 2D- or 3D-T1WI in this observational retrospective study. Although measurement of the percentage brain volume change on 3D-T1WI remains the criterion standard and should be encouraged in future prospective studies, T2-FLAIR-derived percentage lateral ventricle volume change may be a more feasible surrogate when historical or other practical constraints limit the availability of percentage brain volume change on 3D-T1WI.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Zivadinov R, Bergsland N, Korn JR, et al. Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS. AJNR Am J Neuroradiol. 2017. PMID: 29170269. doi:10.3174/ajnr.A5442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。